NASDAQ:ONCO Onconetix (ONCO) Stock Price, News & Analysis $1.06 -0.03 (-2.31%) (As of 10:45 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Onconetix Stock (NASDAQ:ONCO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Onconetix alerts:Sign Up Key Stats Today's Range$1.06▼$1.1050-Day Range$1.08▼$6.2052-Week Range$1.01▼$21.40Volume21,341 shsAverage Volume314,704 shsMarket Capitalization$8.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOnconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Read More… Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Onconetix Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks4th Percentile Overall ScoreONCO MarketRank™: Onconetix scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Onconetix. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioOnconetix has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.62% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently increased by 6.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnconetix does not currently pay a dividend.Dividend GrowthOnconetix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.62% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently increased by 6.90%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 3 people have searched for ONCO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Onconetix to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Onconetix insiders have not sold or bought any company stock.Percentage Held by Insiders11.42% of the stock of Onconetix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.89% of the stock of Onconetix is held by institutions.Read more about Onconetix's insider trading history. Receive ONCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCO Stock News HeadlinesOnconetix files to sell 10.59M shares of common stock for holdersNovember 1, 2024 | markets.businessinsider.comCorrection: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of CreditOctober 3, 2024 | globenewswire.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…November 21, 2024 | Colonial Metals (Ad)Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of CreditOctober 3, 2024 | globenewswire.comWhat's Going On With Onconetix Shares Friday?September 28, 2024 | msn.comUnited States shares higher at close of trade; Dow Jones Industrial Average up 0.20%September 24, 2024 | msn.comOnconetix, Inc. (J4T.MU)September 24, 2024 | nz.finance.yahoo.comOnconetix, Inc. (J4T.F)September 24, 2024 | nz.finance.yahoo.comSee More Headlines ONCO Stock Analysis - Frequently Asked Questions How have ONCO shares performed this year? Onconetix's stock was trading at $7.92 at the start of the year. Since then, ONCO shares have decreased by 86.7% and is now trading at $1.0550. View the best growth stocks for 2024 here. How were Onconetix's earnings last quarter? Onconetix, Inc. (NASDAQ:ONCO) posted its quarterly earnings results on Thursday, August, 29th. The company reported ($9.20) earnings per share (EPS) for the quarter. The business earned $0.71 million during the quarter. When did Onconetix's stock split? Shares of Onconetix reverse split before market open on Tuesday, September 24th 2024. The 1-40 reverse split was announced on Friday, September 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Onconetix's major shareholders? Onconetix's top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (76.04%). How do I buy shares of Onconetix? Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Onconetix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Onconetix investors own include QUALCOMM (QCOM), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID), Plug Power (PLUG) and Sirius XM (SIRI). Company Calendar Last Earnings8/29/2024Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONCO Previous SymbolNASDAQ:ONCO CUSIPN/A CIK1782107 Webwww.bwbioinc.com Phone513-620-4101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,410,000.00 Net MarginsN/A Pretax Margin-3,635.62% Return on Equity-1,472.15% Return on Assets-57.57% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.09 Sales & Book Value Annual Sales$60,000.00 Price / Sales149.22 Cash FlowN/A Price / Cash FlowN/A Book Value$3.01 per share Price / Book0.36Miscellaneous Outstanding Shares8,290,000Free Float7,347,000Market Cap$8.95 million OptionableN/A Beta3.72 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:ONCO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.